Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07310290 · ClinicalTrials.gov registry record
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
A clinical trial of Migraine, sponsored by AbbVie.
- Recruiting
- Registry status
- 189
- Enrollment target
- 3
- Study locations
NCT07310290 is a study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 189 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (47% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07310290, a study of Migraine, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- 189 participants
- Enrollment target
- 3
- Study locations
Study Summary
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks. Ubrogepant is a drug that is approved for the acute treatment of migraine in adults. Approximately 189 participants will be enrolled in approximately 15 sites across the US. Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 13 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Conditions Studied
Study Locations (3)
California
- Neurology and Pain Specialty Center /ID# 278508 - Aliso Viejo
Illinois
- Chicago Headache Center & Research Inst /ID# 272345 - Naperville
Nebraska
- Tri City Research Center, LLC /ID# 278800 - Grand Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07310290
The ClinicalTrials.gov registry entry for NCT07310290 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (47% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 0 interventions.
NCT07310290 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Nebraska.
Frequently Asked Questions
What is clinical trial NCT07310290 about?
NCT07310290 is a clinical study titled "Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks". Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks. Ubrogep...
What is the current status of trial NCT07310290?
This trial is currently recruiting. The enrollment target is 189 participants. The study started on 2026-01-27. Estimated completion is 2027-03.
What conditions does trial NCT07310290 study?
This clinical trial studies the following conditions: Migraine.
Who is sponsoring clinical trial NCT07310290?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07310290 being conducted?
This trial has 3 study locations across California, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.